Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sanofi breaks into first-line multiple myeloma with FDA approval for Sarclisa
Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. That changed Friday. | Since an initial FDA go-ahead in 2020,
Sanofi wins US approval for drug combination to treat multiple myeloma
Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after standard treatments have failed,
Sanofi wins US approval for multiple myeloma drug in newly diagnosed patients
The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's Sarclisa infusion as a treatment for certain types of newly diagnosed multiple myeloma patients.
FDA Approves Isatuximab Plus VRd for Newly Diagnosed Myeloma
The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who are ineligible for ASCT.
Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression
Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.
The American Journal of Managed Care
21h
FDA Approves Isatuximab With VRd as First-Line Option for Transplant-Ineligible Multiple Myeloma
Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot ...
18h
Sanofi Says FDA Approves Sarclisa for Treatment of Blood Cancer Patients
Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for autologous ...
Cure Today
1d
FDA Approves Sarclisa In Newly Diagnosed Transplant-Ineligible Multiple Myeloma
The Food and Drug Administration has approved
Sarclisa
as a first-line treatment for patients with multiple myeloma who are ...
ENDPOINTS NEWS
20h
Sanofi's Sarclisa gets approved as a first-line option for some patients newly diagnosed with multiple myeloma
Despite largely exiting oncology, Sanofi continues to reap the benefit of its multiple myeloma treatment Sarclisa. The FDA on ...
devdiscourse
10h
Latest Health Developments: Key Approvals and Controversies
Recent health developments include the EU backing Novo Nordisk's Wegovy for obesity-related heart conditions, FDA approvals ...
Targeted Oncology
3d
Positive Isa-VRd Trials in Transplant-Ineligible Myeloma Show New Approach
During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, discussed 2 recent trials in multiple myeloma for ...
18d
Sanofi: A Long-Term Cash Cow With High Dividends
Sanofi's Inhibrx acquisition strengthens its position in the global alpha-1 antitrypsin deficiency treatment market. See why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback